ALNY
Alnylam Pharmaceuticals, Inc.
$323.50
+1.91 (+0.59%)
At close · Jul 8
Market Cap
$41.48B
Shares
132,623,144
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-05-27 | 2026-05-20 | |
| 10-Q | 2026-04-30 | 2026-03-31 | |
| 8-K | 2026-04-30 | — | |
| DEF 14A | 2026-04-06 | 2026-05-20 | |
| 8-K | 2026-03-04 | 2026-03-02 | |
| 10-K | 2026-02-12 | 2025-12-31 | |
| 8-K | 2026-02-12 | — | |
| 8-K | 2026-01-12 | 2026-01-11 | |
| 8-K | 2025-12-11 | 2025-12-10 | |
| 8-K | 2025-12-03 | 2025-12-02 | |
| 8-K | 2025-10-30 | — | |
| 10-Q | 2025-10-30 | 2025-09-30 | |
| 8-K | 2025-10-03 | 2025-09-30 | |
| 8-K | 2025-09-12 | — | |
| 8-K | 2025-09-10 | 2025-09-08 | |
| 8-K | 2025-07-31 | — | |
| 10-Q | 2025-07-31 | 2025-06-30 | |
| 8-K | 2025-06-18 | 2025-06-12 | |
| 8-K | 2025-05-13 | 2025-05-08 | |
| 8-K | 2025-05-01 | — | |
| 10-Q | 2025-05-01 | 2025-03-31 | |
| DEF 14A | 2025-03-24 | 2025-05-08 | |
| 8-K | 2025-03-21 | 2025-03-20 | |
| 8-K | 2025-03-05 | 2025-03-03 | |
| 8-K | 2025-02-13 | — | |
| 10-K | 2025-02-13 | 2024-12-31 | |
| 8-K | 2025-01-13 | 2025-01-12 | |
| 8-K | 2024-10-31 | — | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-08-01 | — | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-05-20 | 2024-05-16 | |
| 8-K | 2024-05-02 | — | |
| 10-Q | 2024-05-02 | 2024-03-31 | |
| DEF 14A | 2024-04-01 | 2024-05-16 | |
| 8-K | 2024-03-04 | — | |
| 10-K | 2024-02-15 | 2023-12-31 | |
| 8-K | 2024-02-15 | — | |
| 8-K | 2024-01-19 | 2024-01-12 | |
| 8-K | 2024-01-08 | 2024-01-07 | |
| 8-K | 2023-11-02 | — | |
| 10-Q | 2023-11-02 | 2023-09-30 | |
| 8-K | 2023-10-10 | 2023-10-09 | |
| 8-K | 2023-09-28 | 2023-09-26 | |
| 8-K | 2023-08-03 | 2023-07-31 | |
| 10-Q | 2023-08-03 | 2023-06-30 | |
| 8-K | 2023-07-26 | 2023-07-21 | |
| 8-K | 2023-06-30 | — | |
| 8-K | 2023-05-23 | 2023-05-18 | |
| 10-Q | 2023-05-04 | 2023-03-31 |
Showing 1–50 of 106 filings
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
54 filings
32 filers
Visit website
Investor relations